Abstract Details

Title Comparison of Screening Instruments for Obstructive Sleep Apnea in Adults with Epilepsy

Topic Sleep

Presentation(s) P2 - Poster Session 2 (8:00 AM-9:00 AM)

Poster/Presentation
Number 5-002

Objective We aimed to compare performance characteristics of obstructive sleep apnea (OSA) screens to predict disease severity in adults with epilepsy (AWE).

Background OSA is highly prevalent in AWE, yet screening instruments have not been adequately studied.

Design/Methods Scores for STOP, STOPBANG, STOPBAG, and STOPBAG2, a modified instrument by the Cleveland Clinic, were calculated for a sample of AWE who underwent PSG. STOP was calculated from positive responses to the following items (+1 point each): presence of Snoring, Tiredness/sleepiness/fatigue, Observed apneas, high blood Pressure. STOPBAG and STOPBANG were calculated using those items with addition of: Body mass index ≥30kg/m², Age ≥50yrs, Neck circumference ≥40cm (15.75in) and Male gender. STOPBAG2 was calculated using STOP and male gender and continuous variables for age and BMI. For all instruments, greater scores indicate higher OSA risk. Apnea-hypopnea index (AHI) defined disease severity (mild 5≤15; moderate 15≤30; severe >30). Logistic regression and receiver operating characteristic (ROC) analyses evaluated optimal cutoff values and overall discriminatory power for each instrument.

Results In 133 patients (age 41.9±13.7, 53.6% female, AHI 9.2[2.4,21.7], (32% <5, 32% 5≤15, 19% 15≤30, 17% ≥30), all screening instruments were highly correlated with OSA severity (p<0.001 for all). STOPBAG2 provided best sensitivity for predicting each OSA severity level (mild: 0.86, moderate: 0.79, severe: 0.82) and best specificity for mild OSA (0.86), with comparable specificity for moderate and severe OSA to other instruments. STOPBAG2 had greatest ROC discriminatory power of all instruments for each level of OSA severity (mild: 0.90, moderate: 0.78, severe: 0.80).

Conclusions While all screening instruments were adequate for predicting OSA severity in AWE, the STOPBAG2 has the greatest discriminatory power for predicting all levels of severity, supporting its implementation in epilepsy clinics.

Authors/Disclosures
Maeve M. Pascoe Kane, MD (University of Michigan) PRESENTER	Ms. Pascoe has nothing to disclose.
	No disclosure on file
	No disclosure on file
Irene L. Katzan, MD (Cleveland Clinic, Neurology)	Dr. Katzan has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CSL Behring . The institution of Dr. Katzan has received research support from TEVA Pharmaceuticals.
Nancy R. Foldvary-Schaefer, DO, FAAN (Cleveland Clinic)	Dr. Foldvary-Schaefer has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jazz. The institution of Dr. Foldvary-Schaefer has received research support from Jazz. The institution of Dr. Foldvary-Schaefer has received research support from Suven. The institution of Dr. Foldvary-Schaefer has received research support from Takeda. Dr. Foldvary-Schaefer has received publishing royalties from a publication relating to health care. Dr. Foldvary-Schaefer has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��